메뉴 건너뛰기




Volumn 381, Issue 9880, 2013, Pages 1817-1826

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: A phase 3 comparison of dose intensification with 14-day versus 21-day cycles

(16)  Cunningham, David a   Hawkes, Eliza A a   Jack, Andrew b   Qian, Wendi c   Smith, Paul d   Mouncey, Paul d   Pocock, Christopher e   Ardeshna, Kirit M f,m   Radford, John A g   McMillan, Andrew h   Davies, John i   Turner, Deborah j   Kruger, Anton k   Johnson, Peter l   Gambell, Joanna d   Linch, David m  


Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

EID: 84878112490     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60313-X     Document Type: Article
Times cited : (443)

References (35)
  • 1
    • 0031927984 scopus 로고    scopus 로고
    • New approach to classifying non-hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-hodgkin's lymphoma classification project
    • Armitage JO, Weisenburger DD New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's lymphoma classification project. J Clin Oncol 1998; 16: 2780-95.
    • (1998) J Clin Oncol , vol.16 , pp. 2780-2795
    • Armitage, J.O.1    Weisenburger, D.D.2
  • 2
    • 0027394689 scopus 로고
    • Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-hodgkin's lymphoma
    • Fisher RI, Gaynor ER, Dahlberg S, et al Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002-06.
    • (1993) N Engl J Med , vol.328 , pp. 1002-1006
    • Fisher, R.I.1    Gaynor, E.R.2    Dahlberg, S.3
  • 3
    • 77949830857 scopus 로고    scopus 로고
    • Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL
    • Linch DC, Yung L, Smith P., et al Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL. Br J Haematol 2010; 149: 237-43.
    • (2010) Br J Haematol , vol.149 , pp. 237-243
    • Linch, D.C.1    Yung, L.2    Smith, P.3
  • 4
    • 3242802160 scopus 로고    scopus 로고
    • Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL
    • Pfreundschuh M, Trumper L, Kloess M., et al Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634-41.
    • (2004) Blood , vol.104 , pp. 634-641
    • Pfreundschuh, M.1    Trumper, L.2    Kloess, M.3
  • 5
    • 79957797972 scopus 로고    scopus 로고
    • Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-hodgkin's lymphoma: Final results of the Japan clinical oncology group study, JCOG 9809
    • Ohmachi K, Tobinai K, Kobayashi Y., et al Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809. Ann Oncol 2011; 22: 1382-91.
    • (2011) Ann Oncol , vol.22 , pp. 1382-1391
    • Ohmachi, K.1    Tobinai, K.2    Kobayashi, Y.3
  • 6
    • 3042813710 scopus 로고    scopus 로고
    • Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL
    • Pfreundschuh M, Trumper L, Kloess M., et al Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104: 626-33.
    • (2004) Blood , vol.104 , pp. 626-633
    • Pfreundschuh, M.1    Trumper, L.2    Kloess, M.3
  • 7
    • 20144369743 scopus 로고    scopus 로고
    • ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma
    • Reyes F, Lepage E, Ganem G., et al ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005; 352: 1197-205.
    • (2005) N Engl J Med , vol.352 , pp. 1197-1205
    • Reyes, F.1    Lepage, E.2    Ganem, G.3
  • 8
    • 10744224285 scopus 로고    scopus 로고
    • Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-hodgkin lymphoma
    • Tilly H, Lepage E, Coiffier B., et al Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102: 4284-89.
    • (2003) Blood , vol.102 , pp. 4284-4289
    • Tilly, H.1    Lepage, E.2    Coiffier, B.3
  • 9
    • 0037165261 scopus 로고    scopus 로고
    • CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
    • Coiffier B, Lepage E, Briere J., et al CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42.
    • (2002) N Engl J Med , vol.346 , pp. 235-242
    • Coiffier, B.1    Lepage, E.2    Briere, J.3
  • 10
    • 77957200763 scopus 로고    scopus 로고
    • Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the groupe d'Etudes des lymphomes de l'Adulte
    • Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116: 2040-45.
    • (2010) Blood , vol.116 , pp. 2040-2045
    • Coiffier, B.1    Thieblemont, C.2    Van Den Neste, E.3
  • 11
    • 33745982067 scopus 로고    scopus 로고
    • Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
    • Habermann TM, Weller EA, Morrison V.A., et al Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121-27.
    • (2006) J Clin Oncol , vol.24 , pp. 3121-3127
    • Habermann, T.M.1    Weller, E.A.2    Morrison, V.A.3
  • 12
    • 38549147027 scopus 로고    scopus 로고
    • Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60)
    • for the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)
    • Pfreundschuh M, Schubert J, Ziepert M., et al, for the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105-16.
    • (2008) Lancet Oncol , vol.9 , pp. 105-116
    • Pfreundschuh, M.1    Schubert, J.2    Ziepert, M.3
  • 13
    • 33646004738 scopus 로고    scopus 로고
    • CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the MabThera international trial (MInT) group
    • for the MabThera International Trial (MInT) Group
    • Pfreundschuh M, Trumper L, Osterborg A., et al, for the MabThera International Trial (MInT) Group. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-91.
    • (2006) Lancet Oncol , vol.7 , pp. 379-391
    • Pfreundschuh, M.1    Trumper, L.2    Osterborg, A.3
  • 15
    • 9144237554 scopus 로고    scopus 로고
    • Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
    • Hans CP, Weisenburger DD, Greiner T.C., et al Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-82.
    • (2004) Blood , vol.103 , pp. 275-282
    • Hans, C.P.1    Weisenburger, D.D.2    Greiner, T.C.3
  • 16
    • 77954752069 scopus 로고    scopus 로고
    • Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab
    • Barrans S, Crouch S, Smith A., et al Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010; 28: 3360-65.
    • (2010) J Clin Oncol , vol.28 , pp. 3360-3365
    • Barrans, S.1    Crouch, S.2    Smith, A.3
  • 17
    • 0042449063 scopus 로고    scopus 로고
    • Report of an international workshop to standardize response criteria for non-hodgkin's lymphomas. NCI sponsored international working group
    • Cheson BD, Horning SJ, Coiffier B, et al Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
    • (1999) J Clin Oncol , vol.17 , pp. 1244
    • Cheson, B.D.1    Horning, S.J.2    Coiffier, B.3
  • 18
    • 84870255805 scopus 로고    scopus 로고
    • R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma (DLBCL): Final analysis of the LNH03-6B GELA study
    • (abstr)
    • Delarue R, Tilly H, Salles G.A., et al R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma (DLBCL): final analysis of the LNH03-6B GELA study. J Clin Oncol 2012; 30: 8021 (abstr).
    • (2012) J Clin Oncol , vol.30 , pp. 8021
    • Delarue, R.1    Tilly, H.2    Salles, G.A.3
  • 19
    • 80052980811 scopus 로고    scopus 로고
    • Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-int) or high IPI grade diffuse aggressive non-hodgkin lymphoma (NHL)
    • (abstr)
    • Stiff PJ, Unger JM, Cook J, et al. Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP ± R for eight cycles to CHOP ± R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). J Clin Oncol 2011; 29: 8001 (abstr).
    • (2011) J Clin Oncol , vol.29 , pp. 8001
    • Stiff, P.J.1    Unger, J.M.2    Cook, J.3
  • 20
    • 34447626101 scopus 로고    scopus 로고
    • Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: A multicenter study by GITIL (Gruppo Italiano terapie innovative nei linfomi)
    • Tarella C, Zanni M, Di Nicola M, et al Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia 2007; 21: 1802-11.
    • (2007) Leukemia , vol.21 , pp. 1802-1811
    • Tarella, C.1    Zanni, M.2    Di Nicola, M.3
  • 21
    • 70349128174 scopus 로고    scopus 로고
    • Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: A phase II multicenter study
    • Vitolo U, Chiappella A, Angelucci E., et al Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. Haematologica 2009; 94: 1250-58.
    • (2009) Haematologica , vol.94 , pp. 1250-1258
    • Vitolo, U.1    Chiappella, A.2    Angelucci, E.3
  • 22
    • 77958453257 scopus 로고    scopus 로고
    • High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma
    • Glass B, Ziepert M, Reiser M., et al High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. Ann Oncol 2010; 21: 2255-61.
    • (2010) Ann Oncol , vol.21 , pp. 2255-2261
    • Glass, B.1    Ziepert, M.2    Reiser, M.3
  • 23
    • 80054723216 scopus 로고    scopus 로고
    • First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial
    • (abstr)
    • Le Gouill S., Milpied NJ, Lamy T, et al First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial. J Clin Oncol 2011; 29: 8003 (abstr).
    • (2011) J Clin Oncol , vol.29 , pp. 8003
    • Le Gouill, S.1    Milpied, N.J.2    Lamy, T.3
  • 24
    • 80053385621 scopus 로고    scopus 로고
    • Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized mega-CHOEP trial of the german high-grade non-hodgkin lymphona study group (DSHNHL)
    • (abstr)
    • Schmitz N, Nickelsen M, Ziepert M., et al Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSHNHL). J Clin Oncol 2011; 29: 8002 (abstr).
    • (2011) J Clin Oncol , vol.29 , pp. 8002
    • Schmitz, N.1    Nickelsen, M.2    Ziepert, M.3
  • 25
    • 82255186682 scopus 로고    scopus 로고
    • Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): An open-label randomised phase 3 trial
    • Recher C, Coiffier B, Haioun C., et al Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 2011; 378: 1858-67.
    • (2011) Lancet , vol.378 , pp. 1858-1867
    • Recher, C.1    Coiffier, B.2    Haioun, C.3
  • 26
    • 82255164025 scopus 로고    scopus 로고
    • Intensified chemotherapy for diffuse large B-cell lymphomas
    • Vose JM. Intensified chemotherapy for diffuse large B-cell lymphomas. Lancet 2011; 378: 1828-29.
    • (2011) Lancet , vol.378 , pp. 1828-1829
    • Vose, J.M.1
  • 27
    • 45749152667 scopus 로고    scopus 로고
    • Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers
    • Wilson WH, Dunleavy K, Pittaluga S., et al Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008; 26: 2717-24.
    • (2008) J Clin Oncol , vol.26 , pp. 2717-2724
    • Wilson, W.H.1    Dunleavy, K.2    Pittaluga, S.3
  • 28
    • 79959852471 scopus 로고    scopus 로고
    • Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: A study from the lunenburg lymphoma biomarker consortium
    • Salles G, de Jong D, Xie W, et al Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011; 117: 7070-78.
    • (2011) Blood , vol.117 , pp. 7070-7078
    • Salles, G.1    De Jong, D.2    Xie, W.3
  • 29
    • 70449589073 scopus 로고    scopus 로고
    • MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
    • Savage KJ, Johnson NA, Ben-Neriah S, et al MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 2009; 114: 3533-37.
    • (2009) Blood , vol.114 , pp. 3533-3537
    • Savage, K.J.1    Johnson, N.A.2    Ben-Neriah, S.3
  • 30
    • 70349575802 scopus 로고    scopus 로고
    • Lymphomas with concurrent BCL2 and MYC translocations: The critical factors associated with survival
    • Johnson NA, Savage KJ, Ludkovski O, et al Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009; 114: 2273-79.
    • (2009) Blood , vol.114 , pp. 2273-2279
    • Johnson, N.A.1    Savage, K.J.2    Ludkovski, O.3
  • 31
    • 84855345481 scopus 로고    scopus 로고
    • B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18) (q32;q21): An aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome
    • Li S, Lin P, Fayad L.E., et al B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome. Mod Pathol 2012; 25: 145-56.
    • (2012) Mod Pathol , vol.25 , pp. 145-156
    • Li, S.1    Lin, P.2    Fayad, L.E.3
  • 32
    • 84867060272 scopus 로고    scopus 로고
    • Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
    • Green TM, Young KH, Visco C, et al Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012; 30: 3460-67.
    • (2012) J Clin Oncol , vol.30 , pp. 3460-3467
    • Green, T.M.1    Young, K.H.2    Visco, C.3
  • 33
    • 80755143466 scopus 로고    scopus 로고
    • The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: A bio-CORAL study
    • Thieblemont C, Briere J, Mounier N., et al The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 2011; 29: 4079-87.
    • (2011) J Clin Oncol , vol.29 , pp. 4079-4087
    • Thieblemont, C.1    Briere, J.2    Mounier, N.3
  • 34
    • 57149089307 scopus 로고    scopus 로고
    • Stromal gene signatures in large-B-cell lymphomas
    • Lenz G, Wright G, Dave S.S., et al Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359: 2313-23.
    • (2008) N Engl J Med , vol.359 , pp. 2313-2323
    • Lenz, G.1    Wright, G.2    Dave, S.S.3
  • 35
    • 0034598746 scopus 로고    scopus 로고
    • Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
    • Alizadeh AA, Eisen MB, Davis R.E., et al Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.
    • (2000) Nature , vol.403 , pp. 503-511
    • Alizadeh, A.A.1    Eisen, M.B.2    Davis, R.E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.